$2.97
5.40% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US87167T2015
Symbol
SNPX
Sector
Industry

Synaptogenix Inc Stock price

$2.97
-0.79 21.09% 1M
-1.79 37.62% 6M
-3.83 56.29% YTD
-7.53 71.71% 1Y
-240.78 98.78% 3Y
-83.03 96.55% 5Y
-83.03 96.55% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.17 5.40%
ISIN
US87167T2015
Symbol
SNPX
Sector
Industry

Key metrics

Market capitalization $4.13m
Enterprise Value $-23.28m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 4.73
P/B ratio (TTM) P/B ratio 0.21
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-6.83m
Free Cash Flow (TTM) Free Cash Flow $-4.92m
Cash position $27.41m
EPS (TTM) EPS $-3.71
P/E forward negative
Short interest 0.38%
Show more

Is Synaptogenix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Synaptogenix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Synaptogenix Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Synaptogenix Inc:

Buy
100%

Financial data from Synaptogenix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 0.01 0.01
0% 0%
-
-0.01 -0.01
0% 0%
-
- Selling and Administrative Expenses 5.08 5.08
48% 48%
-
- Research and Development Expense 1.74 1.74
57% 57%
-
-6.83 -6.83
51% 51%
-
- Depreciation and Amortization 0.01 0.01
0% 0%
-
EBIT (Operating Income) EBIT -6.83 -6.83
51% 51%
-
Net Profit -1.71 -1.71
61% 61%
-

In millions USD.

Don't miss a Thing! We will send you all news about Synaptogenix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Synaptogenix Inc Stock News

Neutral
PRNewsWire
16 days ago
NEW YORK , Sept. 11, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly is...
Neutral
PRNewsWire
2 months ago
Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in the treatment of neurodegenerative diseases NEW YORK , July 18, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new...
Neutral
PRNewsWire
3 months ago
Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , June 26, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that the Food & Drug Administration (FDA) has authorized an ...
More Synaptogenix Inc News

Company Profile

Synaptogenix, Inc. operates as a biopharmaceutical company. It develops a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease, which is in the clinical testing stage. The firm also evaluates potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions. The company was founded on October 31, 2012 and is headquartered in New York, NY.

Head office United States
CEO Alan Tuchman
Employees 8
Founded 2012
Website www.synaptogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today